Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2002 Oct 15;20(20):4169-80.
doi: 10.1200/JCO.2002.09.134.

Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings

Filiberto Belli  1 , Alessandro Testori, Licia Rivoltini, Michele Maio, Giovanna Andreola, Mario Roberto Sertoli, Gianfrancesco Gallino, Adriano Piris, Alessandro Cattelan, Ivano Lazzari, Matteo Carrabba, Giorgio Scita, Cristina Santantonio, Lorenzo Pilla, Gabrina Tragni, Claudia Lombardo, Flavio Arienti, Alfonso Marchianò, Paola Queirolo, Francesco Bertolini, Agata Cova, Elda Lamaj, Lucio Ascani, Roberto Camerini, Marco Corsi, Natale Cascinelli, Jonathan J Lewis, Pramod Srivastava, Giorgio Parmiani
Affiliations
Clinical Trial

Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings

Filiberto Belli et al. J Clin Oncol. .

Erratum in

  • J Clin Oncol 2002 Dec 1;20(23):4610

Abstract

Purpose: To determine the immunogenicity and antitumor activity of a vaccine consisting of autologous, tumor-derived heat shock protein gp96-peptide complexes (HSPPC-96, Oncophage; Antigenics, Inc, Woburn, MA) in metastatic (American Joint Committee on Cancer stage IV) melanoma patients.

Patients and methods: Sixty-four patients had surgical resection of metastatic tissue required for vaccine production, 42 patients were able to receive the vaccine, and 39 were assessable after one cycle of vaccination (four weekly injections). In 21 patients, a second cycle (four biweekly injections) was given because no progression occurred. Antigen-specific antimelanoma T-cell response was assessed by enzyme-linked immunospot (ELISPOT) assay on peripheral blood mononuclear cells (PBMCs) obtained before and after vaccination. Immunohistochemical analyses of tumor tissues were also performed.

Results: No treatment-related toxicity was observed. Of 28 patients with measurable disease, two had a complete response (CR) and three had stable disease (SD) at the end of follow-up. Duration of CR was 559+ and 703+ days, whereas SD lasted for 153, 191, and 272 days, respectively. ELISPOT assay with PBMCs of 23 subjects showed a significantly increased number of postvaccination melanoma-specific T-cell spots in 11 patients, with clinical responders displaying a high frequency of increased T-cell activity. Immunohistochemical staining of melanoma tissues from which vaccine was produced revealed high expression of both HLA class I and melanoma antigens in seven of eight clinical responders (two with CR, three with SD, and the three with long-term disease-free survival) and in four of 12 nonresponders.

Conclusion: Vaccination of metastatic melanoma patients with autologous HSPPC-96 is feasible and devoid of significant toxicity. This vaccine induced clinical and tumor-specific T-cell responses in a significant minority of patients.

PubMed Disclaimer

Comment in

Publication types

MeSH terms